NCT02247037View on ClinicalTrials.gov

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 22, 2019

Study Completion Date

January 22, 2019

Conditions
Triple Negative Breast Cancer
Interventions
OTHER

Chemotherapy

Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.

Trial Locations (1)

10029

Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai, New York

Sponsors

Collaborators (1)

Champions Oncology
All Listed Sponsors
collaborator

Champions Oncology

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER